A life sciences consulting firm based in Chicago, Aagami Inc., offers strategic consulting, technology licensing, and business/market research services to support global biotech, pharmaceutical, medical device, and consumer health companies in their initiatives with India and Asia. The document provides details on Aagami's services, approach, clients, leadership team, and case studies highlighting strategic partnerships and licensing deals facilitated by Aagami that helped clients establish partnerships and reduce costs in emerging markets.

1. September 2014
Realizing Possibilities, Together
Aagami ,Inc.|2135 City Gate Lane, Suite 300, Naperville, IL 60653 USA |P: +1-630-364-1837 |www.aagami.com

2. 2 Lifesciences Catalyst
Aagami, Inc.
A life sciences consulting firm based in the suburbs of Chicago offers
For Global Biotech, Pharmaceutical , Medical Devices and Consumer Health products companies, in their initiatives with India, Asia and Emerging Markets.
Strategic Consulting Services
Technology Licensing Services
Business & Market ResearchServices

3. 3 Lifesciences Catalyst
Strategic Consulting Services
In-Licensing or Out-Licensing
Co-Development and Partnerships
Investments to and from India/Asia
Mergers & Acquisitions
Finding the Right Partners
JV and/or Distributors
CRO and CRAMS providers
Contract Sales/Marketing
Contract Manufacturing

4. Offerings in Market/ Business Research
Competitive Landscape Assessments
Analysis of Portfolio and Opportunities identification
Price Discovery Research
Due Diligence
IP and Regulatory Research
Financial Modeling, NPV valuations
New Market Entry strategy
Market development strategy
4 Lifesciences Catalyst

5. 5 Lifesciences Catalyst
Aagami brings
Deep Understanding of business and socio-cultural differences in ways of working
Extensive network with Top LifeSciences companies at CXO levels
Global Deal experience mainly with Western, Japanese and Indian industry
Aagami Partners bring value of combined experience of over 120 years.
Focus on your needs, objectives, success and work as an extension of your team.

6. 6 Lifesciences Catalyst
Strategy
Sector
IN Licensing
OUT Licensing
M & A
Partnership
Co-Development
Regulatory
Market
Research
& Entry
Supply Chain & Distribution
BD
Pharmaceuticals
Biotechnology
CRO & CRAMS
Delivery Technology
Diagnostics
Consumer Health Products
Nutraceuticals/
Cosmeceuticals
Medical Device
Labware
Supported all Business Sectors
The colored boxes represent our experience in that Sector and Strategic area

7. 7 Lifesciences Catalyst
Sample list of Successes (Also see Case Studies for more details)
Licensing and Co-Development partnership for Novel Protein Therapeutic Platform of a German company; Deals done with 2 Major Pharma
Licensing of a dermal delivery system of an Australian company, applicable to both pharmaceutical and personal care products. Licensing Deals signed with 3 companies; Product launched with one; A few more deals in discussion.
Finding customers for Peptides API for a EU conglomerate. Orders received from 8 companies, Few others in final discussions.
Out-Licensing & Distribution partnerships for an Ophthalmic Medical Device company. Signed with a major Pharma Company.
Creation and management of MSDS for a Fortune 100 Chemical company from Midwest US by striking alliance with the right partner in India. 85% Cost reduction was achieved within 6 months of starting operation.

8. 8
Sample list of Aagami Clients
USA
CreAgri
CA
New Heaven Pharma
CT
Advangene
IL
Loyola Univ. Chicago
IL
OncBioMune
LA
Dow Chemicals
MI
ScyFIX
MN
Penwest Corp.
NY
DesignMedix
OR
PLx
TX
International
Phosphagenics
Australia
PeptiSyntha
Belgium
DelMar Pharma
Canada
Affitech
Denmark
Pieris
Germany
Merus
Holland
Venus Remedies
India
Opsona
Ireland
Toppan
Japan
Otago University
New Zealand
Lifesciences Catalyst
Aagami has completed over 100 assignments for more than 50 clients in the last 11+ years.

9. 9 Lifesciences Catalyst
Sample of Aagami contacts in India
We are connected at CXO Level of TOP 100 Lifesciences companies in India. Some of the popular names are below.
Biocon
Intas
Sun Pharma
Cadila
Lupin
Themis
Cipla
MicroLabs
Torrent Pharma
Dr Reddys
Piramal
USV
Glenmark
Reliance
Wockhardt
Hetero Drugs
Strides
Zydus

10. 10 Lifesciences Catalyst
Our Consulting Approach
Setup
•Understand and capture important details about the asset/technology
•Prepare ‘Elevator Pitch’ (EP) customized to specific business culture
•Identify relevant companies from our database and resources
Prospect
•Broadcast EP to Relevant Companies
•Follow-up with phone calls and emails
•Coordinate CDAs with interested Companies
•Supply further info through emails
•Organize conference calls for clarifications
Finalize
•Organize Road show
•Manage appointments with right executives
•Coordinate the logistics of the road show
•Advise on structuring the deal
•Support in negotiations (most critical)

11. 11 Lifesciences Catalyst
Consulting Engagement Model
Dedicated Teamwork (40-80 Hours/month)
Small binding fee for first 6 months
Success fee based on the modified Lehman’s formula
Aagami’s prime focus is CLIENT SUCCESS as that's how we Succeed

12. Research Approach
Study/ Research
•Primary
•Interviews with different stakeholders in the Value chain including opinion leaders, vendors and customers
•Proceedings of Industry events, press conferences and workshops
•Surveys /studies
•Secondary
•Company websites, social media, blogs, forums and groups
•Business directories and databases
•Online and offline libraries and government data
•Economic and Demographic information, Census
•Case studies, Reference Customers, vendors, and associations
Analysis
•Qualitative
•Policy and Regulatory environment
•Competitive Landscape Assessment (CLA)
•Business Analysis, Industry Analysis
•Trends & Drivers,
•Challenges and Risks
•Quantitative
•Market Sizing, Segmentation and Forecasting
•Market share and Opportunity Analysis
Reporting
•Deliverables
•Whitepapers
•Industry Reports
•Investment Models
•Trend Reports
•Tracking Reports
•Competitive Report
•Price Discovery Report
•Corporate Profiles
•Forecasts
•Guesstimates
•NPV Valuation
•Client Presentation and clarifications on client questions
Assess, Analyze, Derive, Synthesize, Report
12 16-Sep-14
Lifesciences Catalyst

13. Research Engagement Models
Need Based
Suits Adhoc and one- off Requirements.
e.g. New Product or Market Entry research, suspect and prospect identification, partner identification, IP Landscape
Dedicated Teams
Suits regular research needs at low operating costs
e.g. Need dedicated support teams for core business or corporate teams
Multi-client studies
Most suitable for multiple clients with common requirements and shared costing
e.g. industry research by association
13 Lifesciences Catalyst 16-Sep-14
Custom engagement models can also be discussed

14. 14 Lifesciences Catalyst
Aagami Leadership Team
Dinesh Jain -Founder CEO
•A business leader in Science and technology industry since 1984 with global experience in starting and managing several technology companies. Has held positions of CEO, President, Vice President. Is a prolific entrepreneur. Has executed severaldozen international deals across 4 continents. He is a regular speaker in International conference son Life Sciences Businesswith India, and also on board of several consulting and research companies
Dr. Mahendra Shah –Company Advisor
•A veteran Scientific leader in Bio-Pharmaceutical field since 1968 . After his PhD, he has worked with some of the top notch companies like Bristol, Squibb, Schering, Lyphomed, Fujisawa, EJ Financials, First Horizon, NextWave. Mahendra is an active Investor in BioPharmaceutical field and is on the Board of several companies across the country.
Dr. Shridhar Andurkar –Scientific Advisor
•Chair and Associate Professor of Pharmaceutical sciences at Midwestern University, Chicago College of Pharmacy, is a Ph D from Auburn University in Medicinal Chemistry, Conducted postdoctoral research at the University of Houston.Dr. Andurkar has publishednumerous papers and made several presentations in this field.He holds a US patent in the area of anticonvulsant drugs and is on the advisory boards of several companies.
Nancy Chew -Regulatory Advisor
•A serial entrepreneur, veteran business leader, biochemist and Pharmacologist by education, Regulatory expert, Several top honors & award winner and Advisor to numerous Life Sciences companies.
•Nancy's accomplishments and achievements of over 39years would take several pages to detail.

15. 15 Lifesciences Catalyst
Aagami Associate Partners
Dr. Hemant Sabharwal M.D., Ph.D. –Founder -Laktobiotics
•15 years of extensive global experience in the Academia and Pharma Industry. Lived and worked in the Middle East, Egypt, Scandinavia, India, and the US. He is also Adjunct Faculty in Department of Medical Microbiology and Immunology, Streptococcal vaccine development, Rockefeller University, New York, NY. To his credit, he has more than 20 publications in peer reviewed Medical and Scientific journals. In the past, he has worked with prestigious institutions such as Institute for Cancer Prevention, NY, Mount Sinai Medical Center, NY, Lund University, Sweden, MonoCarb AB, Sweden, BioCarb AB, Sweden
Anant Kataria –Founder Partner, Sagacious Research
•Anant's expertise lies in supporting Patent Practitioners/Consultants, Patent Licensing Firms/Executives, Law firms in US and Europe by providing a cost-effective back-end team for all their patent related needs. His past work experience is a blend of Intellectual Property Research (IP) in various technical domains and R&D in Automobile Industry.
Vyom Shah, Founder, Phronesis Strategies
•Vyom has worked with companies such as PwC and TCS. With 9+ years of experience, he has extensively worked on several consulting and research cases including NPV valuations across diverse verticals and has served clients ranging from Fortune 500 companies to SMEs, supporting end-to-end engagement lifecycle. He holds an MBA from Lancaster University Management School, UK, specialising in Strategy and Management Consulting and is a qualified Chartered Accountant.
Faiz Wahid -Co-founder, pManifold Research and Consulting
•Faiz started pManifold in 2010 focusing on research, consulting and stakeholder engagement services. Under his leadership the firm has conducted over 10000+ primary customer interviews for various cross sector companies. He holds an MBA from HEC Paris and was an international scholar at the Darden School of Business of the University of Virginia. He also holds a masters in engineering from BITS Pilani and bachelors in engineering from VNIT Nagpur.

16. 16 Lifesciences Catalyst
USA (Head Office)
Aagami, Inc.
2135 City Gate LaneSuite 300
Naperville, IL 60653
P: +1-630-364-1837
INDIA
Aagami
741, Nelson Square
Nagpur MH 440013
P: +91-712-258-6678
Dinesh Jain
Email: dinesh@aagami.com
M:+1 630-853-3520
Godwyn Francis
Email: godwyn@aagami.com
M: +91-787-501-6957
www.aagami.com
CONTACT
© Aagami, Inc. 2014 | All rights reserved

17. Select Case Studies
Strategic Consulting
Business and Market Research
17 Lifesciences Catalyst

18. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Establishing Partnerships for Development and Commercialisation of Novel Class of Protein Drugs
Innovator partners in India to collaborate on a new class of proteins - Anticalins® to develop various programs in Oncology and Ophthalmology. 18
German Biotech company making safer, effective and differentiated Novel drugs
Aagami identified right partners, and took them to 7 interested companies for Anticalins®
With focused efforts 3 companies moved to term sheet level discussions. Aagami kept facilitating and persevering. 2 companies remained for final negotiations.
Aagami maintained its spirits and perseverance knowing Indian ways of working; even when client was ready to give up as per Western ways.
Finally co development partnership happened in next few months with one company in Oncology.
Second company took more time and couple of visits before signing co-development deal for ophthalmic therapy.
Client signed co-development deals with 2 companies in Oct and Dec2013 respectively
Right companies, right advice, structure, perseverance and commitment were the key success factor. in making it happen.
Aagami proved highly influential in negotiations for finalization of the deals due to deep experience in business culture nuances of India.
It brought repeat and referral business to Aagami.
Lifesciences Catalyst

19. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Technology Out-licensing of Transdermal Drug Delivery Technology with 3 Indian Companies
To Out-LicenseTPM® Technology and Co-Develop in clinic products using proprietary Delivery technology and market such products in India and possibly larger region.
19
TPM® Technology and Products Company from Australia
Aagami scanned numerous companies and got 10 relevant companies interested.
Discussion with 8 companies progressed.
Took client to India 3 times for term sheet level meetings and deal signing.
Facilitated entire evaluation and deal structuring process
Aagami made sure testing and other protocols were honoured before deal was made.
During the process Aagami ensured clear understanding despite socio cultural differences in styles of working.
Deals with 3 global companies of India
The first deal was struck for diclofenac topical gel formulation containing TPM platform. The Indian partner not only launched their own product but also out licensed to a major western pharma.
The second alliance was struck for use in Skin Whitening and under eye cream.
Third deal -Aagami was able to facilitate a new business model with this prospect, who using client technology increased bio availability as well as stability of a specific antibiotic.
Lifesciences Catalyst

20. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Reducing cost of creation and management of MSDS
Cost reduction for customized MSDS for various countries with unique regulations for thousands of chemicals it produces. 20
Fortune 100 Chemical company from Midwest US
Client is in Chemicals business for over 100 years across 150 countries and needed to create 1000s of MSDS every month.
This had become very expensive due to complexities and different regulatory needs of various countries .
Aagami analysed the situation and suggested offloading such processes to Indian companies
Aagami scanned though its database and network to identify the right partners.
Performed due diligence on the shortlisted agencies and facilitated discussions and influenced negotiations and deal structuring
Aagami helped strike alliance with the right partner in India.
85% Cost reduction was achieved within 6 months of starting operation
The client continues to employ Global Delivery Model for MSDS creation and management
Lifesciences Catalyst

21. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Global NPV of Technology (in USD Million)
(P) Pessimistic Scenario
Discount rate 8.60%
Year 2012 2013 2014 2015 2016 2017 2018
Time 0 1 2 3 4 5 6
Revenue from Sale of NPTP POC devices - - 20.30 23.62 32.06 40.80 24.93
Revenue from Sale of Treated Cuvette - - 450.00 614.87 815.48 1,021.15 657.19
Total Cost of NPTP POC devices - - 4.10 5.66 7.69 9.78 5.98
Total Cost of Treated Cuvettes - - 175.00 387.88 514.43 644.17 414.57
Commercialisation Costs 400.00 - - - - - -
Total Cash Inflow - - 470.30 638.49 847.54 1,061.96 682.11
Total cash Outflow 400.00 - 179.10 393.54 522.12 653.96 420.55
Net Cash Flow -400.00 - 291.20 244.95 325.43 408.00 261.56
Discount Factor 1.00 0.92 0.85 0.78 0.72 0.66 0.61
Discounted Cash Flow -400.00 - 246.91 191.24 233.96 270.09 159.44
NPV 1,524.77
Assessment of Global Net Present Value (NPV) of a revolutionary
Nanotechnology Based Diagnostic Platform
 Client wanted to commercialize ground breaking technology in the MI
Diagnostics field, and wanted to know its commercial potential so that suitable
licensing fees and model could be determined and also value could be
showcased to Licensees
21
Investors Controlled Innovative technology company
 Aagami involved a team of a senior consultant part time and a business analyst
full time to conduct primary and secondary research involving domain
specialists to capture current market scenario.
 Performed competitive benchmarking to assess a Relative Cost Benefit Index
used later for determining technology platform (product) pricing.
 Projected annual demand for next ten years in three different scenarios -
Median, Optimistic and Pessimistic across multiple disease categories.
 Forecasted Global Average Selling Price (ASP) and Cost associated with capex
and opex
 Validated commercializing options and measured incremental financial scenario
for potential licensees
 Determined the Global Net Present Value (NPV) and created Financial models
 NPV of the technology and indicative licensing fees, along with several insights
generated, served as conclusive guidance to the client for deal-making and
negotiations.
 The client was delighted which also resulted in repeat assignments
Lifesciences Catalyst

22. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Competitive Landscape Analysis in India to finalize Pricing strategy of high-end Cosmeceuticals
Client, a public limited company in Australia needed to get a competitive landscape of prestige skin whitening, anti-ageing and body shaping market in India, to order to device strategy on their pricing and licensing for Indian Market
22
Publicly Listed Australian skincare products & technology company
Aagami involved a team of a senior and a junior researcher part time to conduct secondary research on web and primary research via in person visits to shops, mall and interviews with Industry professionals, Business owners, store managers, salon managers and doctors to assess market and collect data
Identified Competitors and their product ranges with their Price points and feedback from stakeholders
Prepared a crisp and concise report with data, analysis and Unit Price Map in MS-Excel format in an easy to understand and customized views.
Performed competitive benchmarking to assess a Relative Cost Benefit Index and recommended potential product pricing ranges.
As per client, the report was extremely helpful and enlightening in preparing for their trip to India, and proved essential in determining conclusively whether their product range is capable of selling in the Indian market at the equivalent of Australian retail prices
Lifesciences Catalyst